Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
Wanaporn Charoenchokthavee,1 Duangchit Panomvana,1 Virote Sriuranpong,2 Nutthada Areepium1 1Department of Pharmacy Practice, Faculty of Pharmaceutical Science, 2Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Background: Tamoxifen (TAM)...
Guardado en:
Autores principales: | Charoenchokthavee W, Panomvana D, Sriuranpong V, Areepium N |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dd4638e7387d4ee68431b6537441d76d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
por: Charoenchokthavee W, et al.
Publicado: (2017) -
CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
por: Wickramage I, et al.
Publicado: (2017) -
The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics
por: Isabelle Austin-Zimmerman, et al.
Publicado: (2021) -
Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients
por: Areepium N, et al.
Publicado: (2013) -
Prediction of the CYP2D6 enzymatic activity based on investigating of the CYP2D6 genotypes around the vivax malaria patients in Yunnan Province, China
por: Ying Dong, et al.
Publicado: (2021)